Impact of anthracyclines in genomic high-risk, node-negative, HR-positive/HER2-negative breast cancer.

ABSTRACT:

Background

The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor (HR)-positive /human epidermal growth factor receptor 2 (HER2)-negative breast cancer. This study aimed to assess whether patients with RS ≥ 31 would have improved outcomes with the addition of anthracyclines to taxane-based chemotherapy.

Patients and methods

We included patients from TAILORx with RS ≥ 11 who received treatment with either taxanes with cyclophosphamide (TC) or taxane with anthracyclines/cyclophosphamide (T-AC). Distant recurrence-free interval (DRFI), distant recurrence-free survival (DRFS), and overall survival (OS) were compared, controlling for age, tumor si

SUBMITTER: Chen N 

PROVIDER: S-EPMC12753151 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature